Featured Articles
-
Big Pharma Can't Merge Its Way Out Of An Innovation Problem
8/6/2026
Mega-mergers may cut costs, but they won’t fix pharma’s innovation gap. Breakthroughs come through biotech partnerships, writes Sofinnova’s Jim Healy, M.D., Ph.D.
-
Why Life Sciences Demand Venture Formation Over Venture Capital
8/3/2026
The life sciences industry needs venture formation, not traditional VC, to turn academic breakthroughs into successful startups, writes William Garner, M.D.
-
When AI Changes A Deal: Rethinking Risk, Milestones, And Timing In Life Sciences M&A
7/29/2026
AI is shifting life sciences M&A risk from early milestones to later validation, reshaping valuation, diligence, and deal timing, according to experts at Sidley.
-
Bridging The Gap: The Contract-To-Ledger Divide In Life Sciences
7/23/2026
Contract wording in life sciences deals can materially affect revenue recognition, metrics, and disclosures, making early legal-accounting review essential.
-
Rebuilding the Innovation Engine: How We Got Here And What Comes Next
7/20/2026
Federal investment in basic science built America’s innovation engine, but declining support is threatening U.S. leadership, writes Dietrich Stephan, Ph.D.
-
Psychedelics EO May De-Risk Innovation, But Data Is Still King
7/15/2026
A recent Executive Order (EO) de-risks psychedelic drug development by clarifying regulations, but scalable treatment models and rigorous data collection remain critical.
-
Why Breakthrough Research Sits On The Shelf, And What To Do About It
7/13/2026
Healthcare systems must turn proven research into patient care faster with practical infrastructure, product champions, trust, and sustainable funding.
-
Godzilla Vs. The Life Sciences Supply Chain
7/8/2026
A “Godzilla” El Niño could disrupt pharma supply chains, pushing life sciences firms toward AI-driven weather forecasting, scenario planning, and climate resilience.
-
BIO 2026: China, AI, And FDA
7/6/2026
What happened at BIO? This selected coverage from the BIO 2026 meeting in San Diego includes highlights from panels on China, AI, and an FDA Town Hall.
-
Beyond The Fine Print: OPDP's 2026 DTC Letters Redefine Net Impression
6/29/2026
FDA’s OPDP untitled letters show rising scrutiny of DTC ads’ overall impression on consumers and urge companies to balance benefit claims with clear product risks.